![]() | JOHN W HubbardPharmalytics Research Institute, University of Saskatchewan, S7N 3R2, Saskatoon, SK, Canada | College of Medicine, University of Saskatchewan, S7N, Saskatoon, SK, 0W8, Canada ... |
KOL Resume for JOHN W Hubbard
Year | |
---|---|
2004 | Pharmalytics Research Institute, University of Saskatchewan, S7N 3R2, Saskatoon, SK, Canada |
2003 | College of Pharmacy and Nutrition, 110 Science Place, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5C9, Canada |
2001 | College of Pharmacy and Nutrition, University of Saskatchewan, S7N 5C9, Saskatoon, SK, Canada |
2000 | College of Pharmacy and Nutrition, 110 Science Place, University of Saskatchewan, Saskatoon, Saskatchewan, Canada |
1999 | College of Pharmacy & Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, S7N 5C9. Drug Metabolism, Drug Disposition Research Group, University of Saskatchewan, Saskatoon, SK, Canada S7N 5C9 |
1998 | College of Pharmacy & Nutrition, University of Saskatchewan, S7N 5C9, Saskatoon, Saskatchewan, Canada |
1997 | College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan S7N SC9, Canada |
1996 | College of Pharmacy and Nutrition, University of Saskatchewan, 110 Science Place, Saskatoon, SK, S7N 5C9, Canada |
1995 | College of Pharmacy and Medicine, University of Saskatchewan, Saskatoon, Sask., Canada |
1994 | College of Pharmacy, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, S7N OWO |
1993 | Colleges of Pharmacy and Medicine, University of Saskatchewan, S7N 0W0, Saskatoon, Saskatchewan, Canada College of Pharmacy, University of Saskatchewan |
1992 | Colleges of Pharmacy and Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada |
1991 | Colleges of Pharmacy, University of Saskatchewan, S7N 0WO, Saskatoon, Saskatchewan, Canada |
1990 | College of Pharmacy, University of Saskatchewan, Saskatoon, Saskatchewan S7N 0W0 Canada |
1989 | Department of Pharmacy, University of Saskatchewan, Saskatoon, Saskatchewan, Canada |
1988 | Camarillo Neuropsychiatric Institute, University of California, Los Angeles, USA Colleges of Pharmacy and Medicine, University of Saskatchewan, Saskatoon Saskatchewan, Canada Lillhagen Hospital, Göteborg, Schweden |
1987 | College of Pharmacy, University of Saskatchewan, S7N OWO, Saskatoon, Saskatchewan, Canada |
1986 | College of Pharmacy, University of Saskatchewan, Saskatoon, Sask., Canada |
1985 | College of Pharmacy, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; and Departments of Psychiatry and Pharmacology, University of California at Los Angeles, School of Medicine, Los Angeles, California, U.S.A. |
1984 | Colleges of Pharmacy and Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada S7N 0W0 |
1981 | Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada |
1978 | Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada |
1976 | Faculty of Pharmacy, University of Manitoba, Winnipeg 2, Manitoba, Canada |
JOHN W Hubbard: Influence Statistics
Concept | World rank |
---|---|
highly variable drugs | #1 |
metabolites bioequivalence | #2 |
publication chromatography schottenbaumann | #2 |
skeletal prodrugs | #2 |
case nortriptyline | #2 |
amitriptyline tst2 | #2 |
metabolite cpz | #2 |
cpz cpzno | #2 |
fluphenazine decanoate ester | #2 |
dmph mphir | #2 |
methylphenidate time period | #2 |
fluphenazine | #2 |
phenothiazine ring metabolite | #2 |
auc0last | #2 |
stereospecific radioimmunoassays l‐ephedrine | #2 |
8 enantioselective aspects | #2 |
cis ndesmethyldoxepin 15 | #2 |
consequences therapeutic monitoring | #2 |
metabolites fluphenazine | #2 |
dlthreomethylphenidate internal standard | #2 |
quantitation 50 pg | #2 |
plasma cuolometric detection | #2 |
pairwise comparisons tst1 | #2 |
stereoisomerism bioequivalence study | #2 |
cpzno | #2 |
bioequivalence switchability | #2 |
cis amitriptyline | #2 |
dlfenfluramine dlnorfenfluramine | #2 |
tricyclic doxepin humans | #2 |
ibe population bioequivalence | #2 |
impact stereoisomerism | #2 |
8 therapeutic monitoring | #2 |
cis auc0∞ | #2 |
ingestion sustainedrelease formulation | #2 |
flu sesame | #2 |
l‐ephedrine | #2 |
metabolites bioequivalence studies | #2 |
drugs low variability | #2 |
1273 737 ngh | #2 |
cmax auclast ndesmethyldoxepin | #2 |
methylphenidate 8 | #2 |
multisource formulations bioequivalent | #2 |
fluphenazine detection | #2 |
Open the FULL List in Excel | |
Prominent publications by JOHN W Hubbard
Plasma Levels of Fluphenazine in Patients Receiving Fluphenazine Decanoate Relationship to Clinical Response
[ PUBLICATION ]
The levels of fluphenazine and fluphenazine sulphoxide in schizophrenic patients who were randomly assigned to receive either 5 mg or 25 mg of fluphenazine decanoate every two weeks were monitored. Patients treated with 25 mg of fluphenazine decanoate required three months to reach a steady-state plasma level, indicating that those patients who are being converted from oral to depot fluphenazine should continue to receive oral supplementation during the first three months of treatment ...
Known for Plasma Levels | Fluphenazine Decanoate | Schizophrenic Patients | Psychotic Exacerbations | Drug Induced |
Studies on the Mechanism of Absorption of Depot Neuroleptics: Fluphenazine Decanoate in Sesame oil
[ PUBLICATION ]
Purpose. The purpose of the present study was to investigate the pharmacokinetic characteristics of fluphenazine (FLU) and its decanoate (FLU-D) after intravenous and intramuscular administration to dogs.Methods. A group of four beagle dogs was used in all intravenous and intramuscular experiments, with washout periods of no less than three months between doses.Results. After intravenous FLU-D, the pharmacokinetics of the prodrug (mean ± SD) were as follows: Clearance (CL) 42.9 ± 6.3 ...
Known for Sesame Oil | Intramuscular Injections | Proximal Lymph Nodes | Fluphenazine Decanoate | Antipsychotic Agents |
A highly sensitive and specific high-performance liquid chromatographic method with coulometric detection was developed for the simultaneous assay of fluphenazine decanoate and fluphenazine in plasma. The extraction and sample clean-up procedures are simple, rapid to execute, yet yield chromatograms relatively free of any interference from endogenous plasma constituents, such that the extraordinary sensitivity of the coulometric detector can be exploited fully. This is the first ...
Known for Fluphenazine Decanoate | Liquid Chromatography | Plasma Levels | Coulometric Detection | Simultaneous Determination |
It has been shown previously that immediate-release dl-threo-methylphenidate (Ritalin) undergoes stereoselective disposition in human adults as well as in children with attention deficit-hyperactivity disorder. Although the sustained-release formulation of dl-threo-methylphenidate (Ritalin-SR) has been demonstrated to be effective in sustaining the attention of the children with attention deficit-hyperactivity disorder, there are no data on plasma levels of methylphenidate after ...
Known for Hyperactivity Disorder | Attention Deficit | Release Formulation | Plasma Levels | Methylphenidate Administration |
Doxepin is a tricyclic antidepressant marketed as an irrational mixture of cis- and trans-geometric isomers in the ratio of 15:85. A convenient high-performance liquid chromatographic (HPLC) procedure for simultaneous quantitation of geometric isomers of doxepin and N-desmethyldoxepin in plasma and urine is described. The HPLC procedure employed a normal phase system with a silica column and a mobile phase consisting of hexane-methanol-nonylamine (95:5:0.3, v/v/v), a UV detector and ...
Known for Tricyclic Chromatography | Performance Liquid | Geometric Isomers | Trans Doxepin | Irrational Mixture |
Purpose. To test the hypothesis that the pharmacokinetics of d-meth- ylphenidate (d-MPH) would be altered by food ingested before administration of an immediate release formulation (dl-MPH- IR) but not when food is ingested before a slow release formulation (dl-MPH-SR).Methods. A randomized, four-phase, open label, crossover design was conducted in 24 healthy men who each received, on separate occasions, dl-MPH-IR and dl-MPH-SR taken after an overnight fast and 15 min after a ...
Known for Rate Absorption | Mph Food | Release Formulation | Drug Interactions | Action Preparations |
A new analytical method has been developed for the simultaneous quantitation of haloperidol and reduced haloperidol in plasma. The method is based on high performance liquid chromatography (HPLC) with coulometric detection. The extraction and sample clean up procedures are simple and rapid to execute, yet yield chromatograms virtually free of interference from endogenous plasma constituents, such that the extraordinary sensitivity of the coulometric detector can be exploited fully. The ...
Known for Liquid Chromatography | Haloperidol Plasma | 5mg Oral Dose | Detection Limits | Method Developed |
A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia
[ PUBLICATION ]
Following a 2-week placebo lead-in, schizophrenic patients were randomly assigned to fluoxetine 20 mg/day or placebo added to depot neuroleptic for a 6-week, double blind trial. All patients had received a stable dose of depot neuroleptic for at least 6 months and did not meet criteria for depression. Serum samples were obtained at baseline and at weeks 4 and 6. Scores on the negative symptom subscale of the Brief Psychiatric Rating Scale (BPRS) were significantly lower at week 6, ...
Known for Fluoxetine Patients | Negative Symptoms | Controlled Trial | 20 Day | 6 Months |
Clozapine and its two major metabolites, N-desmethylclozapine and clozapine N-oxide were quantified using a high-performance liquid chromatographic method with UV detection in dog plasma following a single dose of clozapine. The analysis was performed on a 5-micrometer Hypersil CN (CPS-1; 250x4.6 mm) column. The mobile phase consisted of acetonitrile-water-1 M ammonium acetate (50:49:1, v/v/v), which was adjusted to pH 5.0 with acetic acid. The detection wavelength was 254 nm. A ...
Known for Liquid Chromatography | Clozapine Noxide | Metabolites Plasma | Mobile Phase | Internal Standard |
A bioequivalence study on perphenazine/amitriptyline combination compared three formulations (TST-1, TST-2 and REF) containing the same nominal dose of perphenazine, while TST-2 contained 20% less amitriptyline than the other two formulations. ANOVA-SNK on log-transformed partial areas AUC024 through AUC0∞ showed the intra-subject variabilities of perphenazine to be consistently higher than those of amitriptyline or nortriptyline. There was also a marked increase in intra-subject ...
Known for Partial Areas | Conventional Release Products | Bioequivalence Studies | Rate Extent | Fell 80–125 |
Radioimmunoassay for psychotropic drugs I: Synthesis and properties of haptens for chlorpromazine
[ PUBLICATION ]
For the development of radioimmunoassay procedures for chlorpromazine and its active metabolites, three chlorpromazine haptens, 7-(or 8-)(3-carboxypropionyl)chlorpromazine, N-(3-carboxypropionyl)desmethylchlorpromazine, and N-(2-carboxyethyl)desmethylchlorpromazine, were synthesized and characterized by GLC--mass spectrometry, PMR spectrometry, and IR spectrophotometry. Each hapten was coupled to bovine serum albumin, and the number of hapten residues per mole of bovine serum albumin ...
Known for Serum Albumin | Psychotropic Drugs | Bovine Spectrophotometry | Mass Spectrometry | Protein Conjugate |
A definitive enantioselective pharmacokinetic evaluation of dl-threo-methylphenidate (MPH) was carried out in 11 healthy volunteers, all of whom received, in a randomized crossover design, three oral administrations of MPH: immediate release (IR), slow release (SR), and SR chewed before swallowing (CH). In addition, all subjects received MPH intravenously (IV) on a separate occasion. Both plasma and urine samples were collected for up to 16 hr after each drug administration. Significant ...
Known for Oral Administration | Mph Lmph | Pharmacokinetic Parameters | Absolute Bioavailability | Dlthreo Methylphenidate |
Haloperidol (HAL) is a potent butyrophenone antipsychotic agent which is reversibly metabolized to reduced haloperidol (RHAL). In order to determine if this reversible metabolic pathway is linked to the debrisoquine 4-hydroxylase isozyme of cytochrome P-450 (P450IID6), HAL (5 mg) or RHAL (5 mg) was orally administered to healthy male volunteers in a randomized crossover design both with and without a prior (1 h) oral dose of quinidine (250 mg bisulfate), a potent inhibitor of this ...
Known for Reduced Haloperidol | Cytochrome P450 | Function Oxygenases | Oxidation Reduction | Plasma Concentration |
Key People For Fluphenazine Decanoate
JOHN W Hubbard:Expert Impact
Concepts for whichJOHN W Hubbardhas direct influence:Fluphenazine decanoate, Highly variable drugs, Plasma levels, Bioequivalence studies, Bioequivalence study, Psychotropic drugs, Partial areas, Plasma concentration.
JOHN W Hubbard:KOL impact
Concepts related to the work of other authors for whichfor which JOHN W Hubbard has influence:Negative symptoms, Human plasma, Mass spectrometry, Liquid chromatography, Fluphenazine decanoate, Antipsychotic drugs, Schizophrenic patients.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |